Synergy (SGYP) PT Lifted to $19 at Canaccord Genuity; 'This Thang Don't Stank'

Pre-Open Stock Movers 06/18: (LMNS) (DGLY) (BMRN) Higher; (HERO) (RATE) (ORCL) Lower (more...)

June 18, 2015 9:34 AM EDT

Hercules Offshore, Inc. (Nasdaq: HERO) 64.3% LOWER; entered into a Restructuring Support Agreement with a steering group of its senior noteholders, to file under Chapter 11.

Bankrate (NYSE:... More

StreetInsider Top 50 Takeover Targets Notable Changes: (KYTH) (TMUS) (RCPT) (SGYP) (TWTR)

June 17, 2015 6:10 PM EDT

A number of changes were made to StreetInsider.coms Top 50 Takeover target list on Wednesday, June 17th:

Kythera Biophrarma (NASDAQ: KYTH) (previously no. 48) was removed after agreeing to be acquired by Allergan (NYSE: AGN) for $75/share, a more than 20% premium to yesterday's market... More

Ironwood Pharmaceuticals (IRWD) PT Trimmed at Wedbush on Positive Data from Competitor Synergy (SGYP)

June 17, 2015 12:27 PM EDT

Wedbush analyst David Nierengarten reiterated a Neutral rating and lowered his price target on Ironwood Pharmaceuticals (NASDAQ: IRWD) to $11.00 (from $13.00) after Synergy Pharmaceuticals (NASDAQ: SGYP) reported positive data for plecanatide in a Ph 3 study of 1346 patients with chronic idiopathic... More

Synergy (SGYP) Seen as Attractive Takeout Target at Cantor Fitzgerald; PT Up to $14

June 17, 2015 11:38 AM EDT

Cantor Fitzgerald analyst Irina Rivkind Koffler reiterated a Buy rating and boosted her price target on Synergy Pharmaceuticals (NASDAQ: SGYP) to $14.00 (from $8.50) following unexpectedly strong Phase III data.

"We view Synergy as an attractive takeout target following its positive Phase III data in... More

Mizuho Maintains Bullish View on Ironwood (IRWD) Linzess Amid Synergy (SGYP) Success

June 17, 2015 8:30 AM EDT

Mizuho Securities analyst Mario Corso offered commentary on Ironwood Pharmaceuticals (NASDAQ: IRWD) after Synergy (NASDAQ: SGYP) reported a positive Phase III plecanatide trial in chronic idiopathic constipation (CIC). Plecanatide is a GCC agonist that could compete with Linzess if approved, the analyst notes.

Shares of Ironwood Pharmaceuticals are down 7.8% early.

The trial met primary endpoint of response rate at the two doses,... More

Synergy Pharma's (SGYP) Phase 3 Trial of Plecanatide in Patients with CIC Mets Primary Endpoint

June 17, 2015 6:37 AM EDT

Synergy Pharmaceuticals Inc. (NASDAQ: SGYP) today announced positive top-line results from the first of two pivotal phase 3 clinical trials evaluating the efficacy and safety of two different plecanatide treatment doses (3.0 mg and 6.0 mg), taken as a tablet once-a-day, in 1,346 adult patients with chronic idiopathic... More